Efficacy/Safety Study to Explore a New Topical Formulation in Atopic Dermatitis (Phoenix)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01691209
Recruitment Status : Withdrawn
First Posted : September 24, 2012
Last Update Posted : August 13, 2013
Information provided by:

Brief Summary:
The study shall explore whether treatment of atopic dermatitis is equally effective with Phoenix medical device as compared to standard therapy (Hydrocortisone cream).

Condition or disease Intervention/treatment Phase
Dermatitis, Atopic Device: Phoenix (BAY81-2996) Drug: 1% Hydrocortison cream Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: An Investigator-blinded, Randomized, Monocentre, 3-arm, Active Controlled Pilot Trial to Explore the Efficacy and Safety of a Topical Medical Device in Patients With Mild to Moderate Atopic Dermatitis in an Intra-individual Comparison With a Standard Therapy (1% Hydrocortisone Cream) and Untreated Skin
Study Start Date : October 2013
Estimated Primary Completion Date : April 2014
Estimated Study Completion Date : June 2014

Arm Intervention/treatment
Experimental: Phoenix
Application over 29 days twice daily
Device: Phoenix (BAY81-2996)
Topical formulation applied to the skin

Active Comparator: Hydrocortison
Application over 29 days twice daily
Drug: 1% Hydrocortison cream
1% Hydrocortison cream applied to the skin

No Intervention: Untreated skin
Participants will be observed over 29 days without study treatment

Secondary Outcome Measures :
  1. Number of participants with abnormal vital signs [ Time Frame: Up to 10 weeks ]
    Vital signs consist of blood pressure, heart rate and body temperature.

  2. Number of participants with adverse events as a measure of safety and tolerability [ Time Frame: Up to 10 weeks ]

Other Outcome Measures:
  1. Local scored atopic dermatitis (SCORAD) as clinical assessment by means of the intensity items of the SCORAD index [ Time Frame: Up to 29 days ]
  2. Transepidermal water loss (TEWL) as a measure for skin barrier function [ Time Frame: Up to 29 days ]
  3. Skin hydration by means of corneometry [ Time Frame: Up to 29 days ]
  4. Erythema by means of chromametry [ Time Frame: Up to 29 days ]
  5. Intensity of pruritus by means of visual analogue scale (VAS) [ Time Frame: Up to 29 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female Caucasians aged between 18 and 60 years
  • Patients with mild atopic dermatitis (AD) presenting a scoring AD (SCORAD) rating below 50
  • Skin type I - IV according to Fitzpatrick
  • Acute AD symptoms on each assessment areas (local SCORAD ≥ 3 and <= 12) at Baseline
  • Acute symptom of pruritus at Baseline

Exclusion Criteria:

  • Any other skin disease at the test area that would interfere with the clinical assessment in the opinion of the investigator
  • Moles, tattoos, strong pigmentation, or scars at the test area that would interfere with the clinical assessment
  • Regular intake of antiphlogistic drugs (for example nonsteroidal anti-inflammatory drugs [NSAIDs])
  • Any condition or treatment which might influence the trial (e.g. any treatment with topical antibiotics, antifungals, or corticoids) within 14 days prior to screening as well as during the trial (exception: topical treatment of AD lesions other than the test areas (for example, face) with low potency steroids restricted to small areas)
  • UV-therapy or the use of solarium within 30 days before screening as well as during the trial
  • Any alternative treatment of AD (e.g. acupuncture, kinesiology, and homoeopathy) within 30 days before screening as well as during the trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01691209

Münster, Nordrhein-Westfalen, Germany, 48155
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer

Additional Information:
Responsible Party: Head Medical Affairs, Bayer HealthCare AG, Consumer Care Identifier: NCT01691209     History of Changes
Other Study ID Numbers: 16200
2012-001504-38 ( EudraCT Number )
First Posted: September 24, 2012    Key Record Dates
Last Update Posted: August 13, 2013
Last Verified: August 2013

Keywords provided by Bayer:
mild atopic dermatitis

Additional relevant MeSH terms:
Dermatitis, Atopic
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Immune System Diseases
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Cortisol succinate
Anti-Inflammatory Agents